Biopharmaceutical company focused on developing targeted therapies for genetically defined cancers.
Day One Biopharmaceuticals, Inc. is an innovative clinical-stage biopharmaceutical firm specializing in the development and commercialization of targeted therapies tailored for patients diagnosed with genetically defined cancers. Founded in 2018 and based in South San Francisco, California, the company is dedicated to advancing novel treatments that address critical unmet needs in oncology.
At the forefront of its pipeline is DAY101, the company's lead product candidate. DAY101 is an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase (RAF) inhibitor currently undergoing Phase II clinical trials. These trials focus on pediatric patients suffering from relapsed or progressive low-grade glioma, demonstrating Day One's commitment to advancing therapies for vulnerable patient populations.
In addition to DAY101, Day One Biopharmaceuticals is actively developing Pimasertib, an oral small molecule inhibitor targeting mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). This compound holds promise for its potential to inhibit cancer cell growth by disrupting critical signaling pathways involved in tumor progression.
Driven by a mission to transform cancer treatment paradigms, Day One Biopharmaceuticals collaborates with leading researchers and institutions to accelerate the development and deployment of its innovative therapies. The company's strategic location in the biotechnology hub of South San Francisco positions it at the forefront of cutting-edge research and development in oncology, poised to make significant strides in improving patient outcomes worldwide.